Off Label Use of Propranolol for Infancy Hemangiomas
Status:
Completed
Trial end date:
2013-10-01
Target enrollment:
Participant gender:
Summary
Propranolol use for infancy hemangiomas is of world wide interest due to low cost and
presumed efficacy. The investigators hypothesized that the drug ist highly active against
growing hemangiomas in problematic sites and that there are little side effects.
This observational study was undertaken in an uncontrolled fashion to determine sample size,
design and and tools for a later randomized controlled trial on propranolol versus physical
therapy (i.e.cryotherapy) which is the most prevalent treatment for the condition. During
this initial series side effects and relevant design aspects became evident which warrant
expedited reporting.